Groundbreaking remote robotic surgery: Patient was in Africa; doctor was in Florida
Three months later, he underwent a procedure to cut out the cancer from a surgeon who has done tens of thousands of similar procedures.
But the doctor performing the surgery was 7,000 miles away -- in Orlando, Florida.
MORE: Doctors save baby's life with first-ever gene fix for deadly rare disease
Da Silva was the first patient of a groundbreaking human clinical trial approved by the U.S. Food and Drug Administration to test transcontinental robotic telesurgery.
"We've been working on this really for two years," Dr. Vipul Patel, the medical director of the Global Robotic Institute at Orlando's Advent Health, told ABC News after completing the surgery. "We traveled the globe, looking at the right technologies."
ABC News' medical correspondent Dr. Darien Sutton was granted exclusive access to the remote surgery in a special report that aired June 16 on ABC News Live Prime with Linsey Davis.
Prostatectomy, a surgical procedure that removes part or all the prostate, has more recently been done with a sophisticated robotic surgery system.
Instead of scrubbing into the operating room, surgeons operate on patients via a multimillion-dollar robot with enhanced visuals and nimble controls.
MORE: Kraft Heinz to remove artificial dyes from food products over next 2 years
Using a robot allows for the procedure to be less invasive, more precise and typically comes with a faster recovery time.
While surgeons are typically near the patient they are operating on, Patel and his team were eager to test whether the surgery could be done long distance using a fiber optic cables.
"I think the humanitarian implications are enormous," Patel said. "Internationally, obviously, there's so many underserved areas of the world."
Patel also pointed out that rural areas within the U.S. could benefit by helping surgeons learn new procedures from a distance or helping patients from a distance if complications arise during surgery.
"Emergency room physicians will have technology that can be remotely accessible to surgeons, maybe even in the ambulance, where people can get remote interventions if they can't make it to the hospital," Patel said.
Patel had his surgical team in the operating room in Angola and were prepared for any potential issues, in case they arose.
"We made sure we had plan A, B, C, and D. I always have my team where the patient is," Patel said. "So, in case something happened with" the telecommunications, "the team would just take over and finish the case and do it safely."
Patel said he plans to submit the data from the surgery back to the FDA for teams there to review in the hopes he will be able to do more telesurgeries.
"It was a small step for a surgeon, but it was huge leap for health care," he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
5 hours ago
- Forbes
Common Concerns About Clinical Trials—And What We Can Do About Them
Sonali Bloom is CEO of 20/20 Onsite. When people hear the term 'clinical trial,' they often imagine someone with a serious illness, desperate for a last-resort treatment, being poked and prodded in a lab. These images are persistent, but far from the truth. In my years of experience working with clinical trials, I've learned that while some of the concerns people have are valid, many are rooted in misunderstanding. These misconceptions have a significant impact on how broad and effective our clinical research can be. When we can't recruit or retain the right participants, it slows the pace of medical advancement for everyone. But the good news is that we have real, actionable ways to address these issues, starting with education and a patient-first approach to clinical trial design. Not Just For The Sick One of the most common misconceptions I hear is that trials are only for people who are seriously ill. In reality, healthy volunteers play a critical role in clinical research. Drug developers need a baseline, like a statistical 'blank slate,' to see how new treatments affect the body without the complications of an existing condition. This misconception often goes hand in hand with the belief that trials are only for those who have exhausted every other option. That narrative is just as inaccurate. Many trials are designed specifically for people at the beginning of their treatment journey. Clinical trials can offer alternatives that are less invasive or more promising, such as a pill for an ophthalmologic condition instead of injections or surgery. That alone can be a compelling reason to participate in a trial sooner, rather than later. We can't talk about hesitations around clinical trials without addressing the issue of historical distrust. In some communities, especially those that have been mistreated or exploited by the medical establishment, this skepticism is deep-rooted and understandable. But today, clinical research is one of the most highly regulated parts of healthcare. Participant safety is paramount, and researchers are required to adhere to strict protocols and uphold stringent ethical standards. Nonetheless, trust is earned, not granted. The impact of these concerns is not academic. They directly affect who participates in trials and who doesn't. Right now, trial participants tend to come from a narrow demographic, often concentrated in cities around research hubs. This lack of variety in age, background, and lived experience can lead to blind spots in treatment efficacy, safety, and applicability. Building Trust And Breaking Barriers Let's be honest: Participating in a clinical trial can be inconvenient. There may be travel involved, time away from work or family, and experimental medical procedures don't always work. But the reality is changing fast. We're seeing a wave of innovation in technology and trial design aimed at reducing patient burden. Remote monitoring, mobile clinics and at-home test kits are making participation more convenient and accessible. Why drive to a hospital when a nurse can come to you, or you can test yourself at home and log your data on a smartphone? These kinds of features are essential if we want to recruit and retain a more diverse group of participants. And for many patients, financial compensation is an added incentive. In some cases, you're essentially receiving cutting-edge care, often years before it's widely available, for free. Education is our strongest tool for getting the truth out. When people understand the purpose, value and reality of clinical research—not just for themselves, but for society—it helps normalize the process and reframes the conversation. Clinical trials are an integral part of the healthcare ecosystem. Helping people see that connection builds trust and encourages a wider swath of society to participate. The result: better outcomes on all sides. Education also helps foster a sense of gratitude. When you understand the rigorous process a drug or procedure undergoes before it reaches your pharmacy or doctor's office, you're more likely to appreciate the people who helped test and develop it. Even if the benefit of taking part in a clinical trial isn't immediate or personal, your participation could help a family member, a neighbor or someone else in your community down the line. When more people see trials in this light, we can help shift the conversation from 'Why me?' to 'Why not me?' Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Associated Press
11 hours ago
- Associated Press
Nestmedic Selects Curavit Clinical Research as U.S. CRO Partner for Pioneering Prenatal Monitoring Trial
BOSTON and WARSAW, Poland, July 21, 2025 /PRNewswire/ -- Curavit Clinical Research, 'The Innovation CRO', is proud to announce its selection by Nestmedic S.A. to lead the U.S. clinical trial of PregnaOne, an innovative remote prenatal monitoring solution. This milestone partnership was recently shared on LinkedIn by Nestmedic CEO Jacek Gnich and Curavit leadership. The upcoming Non-Significant Risk (NSR) study will enroll 50 expectant mothers in the U.S. to evaluate the safety and effectiveness of PregnaOne during home use. The study is designed to generate foundational evidence to support future regulatory approval in the U.S. Curavit will manage all aspects of the trial, including IRB submissions, site selection, contract and monitoring, data management, clinical data capture software selection, data analytics, and preparation of the Clinical Study Report (CSR). 'We are honored to support Nestmedic in bringing PregnaOne to market,' said Joel Morse, CEO and Co-founder of Curavit Clinical Research. 'Their mission to improve prenatal care through remote monitoring perfectly aligns with Curavit's vision to partner with innovative medical device companies that are working to expand access to healthcare.' Trial Highlights: 'We are building technology with empathy at its core,' said Jacek Gnich, CEO of Nestmedic. 'Curavit's innovation forward approach, medical device expertise, and deep clinical trial experience make them the ideal partner to run this pivotal study in the U.S.' About Curavit Clinical Research Curavit Clinical Research, The Innovation-CRO, designs and executes modern clinical trials for medical devices, digital therapeutics, and novel pharmaceuticals. Headquartered in Boston, Curavit operates nationwide with additional offices in New York, Salt Lake City, and San Diego. Learn more at About Nestmedic S.A. Nestmedic is a Polish medtech company redefining prenatal care with PregnaOne, an AI-enabled remote monitoring solution that empowers patients and providers with real-time, continuous insight into fetal and maternal well-being. View original content to download multimedia: SOURCE Curavit Clinical Research
Yahoo
11 hours ago
- Yahoo
Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer (TNBC)
LUND, SWEDEN / / July 17, 2025 / Cantargia (STO:CANTA) Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well tolerated with neutropenia and asthenia as the most common side effects The primary endpoint, overall response rate (ORR),was similar in the nadunolimab plus carboplatin/gemcitabine treated group and the carboplatin/gemcitabine reference group TRIFOUR is an exploratory open label randomized Phase 1b/2 clinical study conducted by the Spanish Breast Cancer Group (GEICAM).The objective is to evaluate early signals of efficacy of Cantargia's IL1RAP antibody nadunolimab in TNBC, with unconfirmed ORR as primary endpoint. The ORR was 40% in the Ph2 study in the nadunolimab plus GC treated patients. As reference, the ORR in the GC group was 43%. Subgroup analyses of the data are ongoing. The tolerability of the combination was acceptable and in line with previous trials combining nadunolimab and chemotherapy. Most common side effects in this trial were neutropenia and asthenia with no notable differences between the two study arms. "TNBC is a heterogeneous and difficult to treat disease, with a high unmet medical need. We welcome the efforts to explore new treatments and appreciate the learnings we are making from the TRIFOUR study. We now await the outcome of further analyses from the study, including overall survival," said Dr. Eva Carrasco, CEO of GEICAM. "We are pleased to have the opportunity to collaborate with GEICAM and explore nadunolimab in the TNBC indication. While the preliminary ORR results of the Phase 2 part of the TRIFOUR trial do not match those obtained in the Phase 1b part of the trial, the study continues and we will now await the mature survival data." said Damian Marron, interim CEO of Cantargia. "Following the signing of our CAN10 agreement earlier this week, we will be undertaking a detailed portfolio discussion to define our plans for the further development of nadunolimab". The TRIFOUR Ph1b/2 study first enrolled 15 patients in a preliminary phase 1b dose-ranging part, which showed an acceptable safety profile with promising efficacy including 73% unconfirmed ORR (60% confirmed) in first-line (1L) or second-line (2L) patients with metastatic TNBC. In the Phase 2 part of the trial, patients were randomized to two study groups with nadunolimab + GC treatment in the experimental group (n=51) and GC alone in the reference group (n=48). Nadunolimab (2.5 mg/kg) and GC were given twice per cycle in 3- or 4-week cycles. The objective of the study was to identify early signals of efficacy, with an internal GC group for reference. RECIST 1.1 criteria were used to evaluate the preliminary ORR which was based on a minimum of 2 CT scans (approx. 3 months treatment) from the 97 TNBC patients included in the efficacy analyses. Among these, 20 patients (40%) showed unconfirmed complete response (CR) or partial response (PR) in the nadunolimab + GC arm vs. 20 patients (43%) in the chemotherapy arm. This data in 1L and 2L patients is higher than the historical response rate of approximately 30% reported for GC alone in 1L, 2L and third-line patients [1], and similar to 1L TNBC patients treated with chemotherapy alone [2]. Nadunolimab has been tested in over 300 patients with metastatic cancer. Previous data in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) indications have shown promising results for nadunolimab in combination with chemotherapy in these indications [3,4], and nadunolimab is granted Fast Track designation from the U.S. Food and Drug Administration (FDA) in PDAC patients with high expression levels of IL1RAP. Nadunolimab is currently being tested inpatients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in an investigator-initiated clinical study at The University of Texas MD Anderson Cancer Center. More details of the TRIFOUR study will be communicated at an upcoming scientific conference. References[1] O'Shaughnessy, J Clin Oncol 2014, 32:3840-3847[2] Cortes N Engl J Med 2022, 387: 217-226[3] van Cutsem et al, Clin Cancer Res 2024, 30: 5293-5303[4] Paulus et al, Lung Cancer 2025, For further information, please contactDamian Marron, Interim CEOTelephone: +46 (0)46-275 62 60E-mail: This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-07-17 21:30 CEST. About CantargiaCantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on hidradenitis suppurativa and systemic sclerosis. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at About nadunolimab (CAN04)The antibody nadunolimab binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1α and IL-1β signaling. Nadunolimab can thereby counteract the IL-1 system which contributes to the immune suppressive tumor microenvironment and the development of resistance to chemotherapy. Nadunolimab is investigated in multiple clinical trials; the phase I/IIa trial CANFOUR, NCT03267316, evaluates nadunolimab in combination with standard chemotherapies in patients with pancreatic ductal adenocarcinoma (PDAC) (gemcitabine/nab-paclitaxel) or non-small cell lung cancer (NSCLC) (platinum-based chemotherapies). Positive data show durable responses for combination therapy in 73 PDAC patients, resulting in a median iPFS of 7.2 months and median OS of 13.2 months. An even higher median OS of 14.2 months was observed in a subgroup of patients with high tumor levels of IL1RAP. Strong efficacy was also observed in 40 NSCLC patients with median PFS of 7.2 months and a response rate of 55%; even higher responses were observed in non-squamous NSCLC patients. Early efficacy data from the phase 1b/2 trial TRIFOUR, NCT05181462, also shows signs of promising efficacy in TNBC with a 60% response rate for nadunolimab combined with carboplatin/gemcitabine. About GEICAMGEICAM is the leader group in breast cancer research in Spain with a recognized worldwide prestige. It is formed by more than 900 experts, who work in 220 institutions throughout its establishment in 1995 until now GEICAM has performed more than a hundred of studies in which almost 68,000 women and men have has a large multidisciplinary team specialized in the management of clinical trials and other studies, which collaborates with clinical researchers in the design and implementation of clinical trials, as well as in their execution and dissemination in forums and high-impact scientific more information, you can visit the official website or follow us on Twitter @GEICAM, @GEICAMujer, and on AttachmentsCantargia announces preliminary topline efficacy results from the phase 2 TRIFOUR trial of nadunolimab in advanced triple-negative breast cancer (TNBC) SOURCE: Cantargia View the original press release on ACCESS Newswire
